(PODD) Insulet - Ratings and Ratios
Insulin, Pod, CGM-Integrated, Onpro
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 50.8% |
| Value at Risk 5%th | 75.7% |
| Relative Tail Risk | -9.38% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.26 |
| Alpha | -2.41 |
| CAGR/Max DD | -0.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.635 |
| Beta | 0.821 |
| Beta Downside | 1.210 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.31% |
| Mean DD | 24.11% |
| Median DD | 19.69% |
Description: PODD Insulet October 16, 2025
Insulet Corporation (NASDAQ:PODD) designs, manufactures, and markets tubeless insulin-delivery systems for people with insulin-dependent diabetes, primarily in the United States but increasingly abroad. Its flagship Omnipod platform includes the Omnipod 5 automated insulin delivery (AID) system-featuring a proprietary algorithm that wirelessly links the pod to a third-party continuous glucose monitor (CGM)-and the Omnipod DASH system, which pairs a Bluetooth-enabled pod with a smartphone-style personal diabetes manager.
Beyond diabetes care, Insulet supplies specialized pods to Amgen for the Neulasta Onpro kit, a chemotherapy-support device that lowers infection risk. Sales are channeled through pharmacies and independent distributors, and the company has been operating since its 2000 incorporation in Acton, Massachusetts.
Key recent metrics: FY 2023 revenue reached $2.53 billion, up 14 % year-over-year, driven by a 23 % increase in Omnipod 5 shipments; the U.S. diabetes device market is projected to grow at a 9 % CAGR through 2028, bolstered by expanding tele-health adoption and favorable reimbursement trends for AID systems. Insulet’s market share in the tubeless pump segment rose to roughly 45 % in Q3 2024, reflecting strong brand penetration and a growing preference for patch-pump technology over traditional pumps.
For a deeper quantitative assessment, the ValueRay platform’s detailed valuation models for PODD can help you evaluate the stock’s upside potential.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (246.2m TTM) > 0 and > 6% of Revenue (6% = 151.3m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 5.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 48.05% (prev 67.31%; Δ -19.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.18 (>3.0%) and CFO 533.7m > Net Income 246.2m (YES >=105%, WARN >=100%) |
| Net Debt (273.9m) to EBITDA (451.2m) ratio: 0.61 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (70.7m) change vs 12m ago -4.45% (target <= -2.0% for YES) |
| Gross Margin 71.46% (prev 69.36%; Δ 2.10pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 83.30% (prev 65.57%; Δ 17.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.85 (EBITDA TTM 451.2m / Interest Expense TTM 53.1m) >= 6 (WARN >= 3) |
Altman Z'' 3.76
| (A) 0.40 = (Total Current Assets 1.86b - Total Current Liabilities 647.7m) / Total Assets 3.03b |
| (B) 0.06 = Retained Earnings (Balance) 185.8m / Total Assets 3.03b |
| (C) 0.12 = EBIT TTM 363.7m / Avg Total Assets 3.03b |
| (D) 0.12 = Book Value of Equity 199.0m / Total Liabilities 1.65b |
| Total Rating: 3.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.41
| 1. Piotroski 9.0pt |
| 2. FCF Yield 1.99% |
| 3. FCF Margin 16.70% |
| 4. Debt/Equity 0.75 |
| 5. Debt/Ebitda 0.61 |
| 6. ROIC - WACC (= 0.86)% |
| 7. RoE 18.27% |
| 8. Rev. Trend 98.10% |
| 9. EPS Trend 76.49% |
What is the price of PODD shares?
Over the past week, the price has changed by -6.88%, over one month by -9.84%, over three months by -12.95% and over the past year by +7.57%.
Is PODD a buy, sell or hold?
- Strong Buy: 14
- Buy: 6
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the PODD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 378.2 | 28.6% |
| Analysts Target Price | 378.2 | 28.6% |
| ValueRay Target Price | 297.4 | 1.1% |
PODD Fundamental Data Overview December 10, 2025
P/E Trailing = 86.1017
P/E Forward = 54.9451
P/S = 8.2677
P/B = 15.4735
P/EG = 3.3143
Beta = 1.375
Revenue TTM = 2.52b USD
EBIT TTM = 363.7m USD
EBITDA TTM = 451.2m USD
Long Term Debt = 934.9m USD (from longTermDebt, last quarter)
Short Term Debt = 96.4m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 273.9m USD (from netDebt column, last quarter)
Enterprise Value = 21.12b USD (20.85b + Debt 1.03b - CCE 757.4m)
Interest Coverage Ratio = 6.85 (Ebit TTM 363.7m / Interest Expense TTM 53.1m)
FCF Yield = 1.99% (FCF TTM 421.2m / Enterprise Value 21.12b)
FCF Margin = 16.70% (FCF TTM 421.2m / Revenue TTM 2.52b)
Net Margin = 9.76% (Net Income TTM 246.2m / Revenue TTM 2.52b)
Gross Margin = 71.46% ((Revenue TTM 2.52b - Cost of Revenue TTM 719.7m) / Revenue TTM)
Gross Margin QoQ = 72.22% (prev 69.67%)
Tobins Q-Ratio = 6.97 (Enterprise Value 21.12b / Total Assets 3.03b)
Interest Expense / Debt = 1.51% (Interest Expense 15.6m / Debt 1.03b)
Taxrate = 28.66% (35.2m / 122.8m)
NOPAT = 259.4m (EBIT 363.7m * (1 - 28.66%))
Current Ratio = 2.87 (Total Current Assets 1.86b / Total Current Liabilities 647.7m)
Debt / Equity = 0.75 (Debt 1.03b / totalStockholderEquity, last quarter 1.38b)
Debt / EBITDA = 0.61 (Net Debt 273.9m / EBITDA 451.2m)
Debt / FCF = 0.65 (Net Debt 273.9m / FCF TTM 421.2m)
Total Stockholder Equity = 1.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.13% (Net Income 246.2m / Total Assets 3.03b)
RoE = 18.27% (Net Income TTM 246.2m / Total Stockholder Equity 1.35b)
RoCE = 15.94% (EBIT 363.7m / Capital Employed (Equity 1.35b + L.T.Debt 934.9m))
RoIC = 9.53% (NOPAT 259.4m / Invested Capital 2.72b)
WACC = 8.66% (E(20.85b)/V(21.88b) * Re(9.04%) + D(1.03b)/V(21.88b) * Rd(1.51%) * (1-Tc(0.29)))
Discount Rate = 9.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.57%
[DCF Debug] Terminal Value 66.08% ; FCFE base≈351.5m ; Y1≈230.8m ; Y5≈105.5m
Fair Price DCF = 25.12 (DCF Value 1.77b / Shares Outstanding 70.3m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 76.49 | EPS CAGR: 33.47% | SUE: 0.45 | # QB: 0
Revenue Correlation: 98.10 | Revenue CAGR: 24.80% | SUE: 2.47 | # QB: 16
EPS next Quarter (2026-03-31): EPS=1.19 | Chg30d=+0.036 | Revisions Net=+6 | Analysts=18
EPS next Year (2026-12-31): EPS=6.17 | Chg30d=+0.366 | Revisions Net=+22 | Growth EPS=+26.2% | Growth Revenue=+20.4%
Additional Sources for PODD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle